Sort   by:  
 Page size 
GenomicsCancer Genetic Markers of Susceptibility (CGEMS) Prostate Cancer Genome-Wide Association Study (GWAS) - Primary Scan (Stage 1) - PLCO Screening Trial

The Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer genome-wide association study (GWAS) included genotyping approximately 550,000 SNPs (Phase 1A with HumanHap300 and Phase 1B HumanHap240, both from Illumina, San Diego, CA) in 1,172 prostate cancer patients and 1,157 controls...

phs000207.v1.p1 | EGA
GenomicsGlioma GWAS summary statistics
Meta-analysis association statistics from case-control analysis (includes imputed SNPs)
EGAD00010001657 | EGA
GenomicsSummary statistics from genome-wide association study in glioma of 12,488 cases and 18,169 controls.
Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two new GWAS, which totaled 12,488 cases and 18,169 controls. We identified five ...
EGAS00001003372 | EGA
GenomicsGlioma GWAS summary statistics DAC
Data Access Committee EGAC00001001116
EGAC00001001116 | EGA
GenomicsNational Cancer Institute Genome-Wide Association Study of Renal Cell Carcinoma

The National Cancer Institute (NCI) genome-wide association study (GWAS) of renal cell carcinoma (RCC) was conducted to investigate common genetic variants associated with RCC risk. The GWAS includes 1,453 RCC cases and 3,531 controls of European background from 4 studies (3 cohort, 1 case-con...

phs000351.v1.p1 | EGA
UnknownGenome-wide association study identifies multiple risk loci for renal cell carcinoma.
Not available
S-EPMC5472706 | biostudies-literature
Sort   by:  
 Page size